Skip to main content

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 162

Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Emavusertib in Combination with Cisplatin, Gemcitabine, and Durvalumab for the Treatment of Advanced Unresectable or Metastatic Biliary Tract Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Status: Active
Location: See ClinicalTrials.gov
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Status: Active
Location: See ClinicalTrials.gov
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Status: Active
Location: See ClinicalTrials.gov
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Status: Active
Location: See ClinicalTrials.gov
Maintenance Zanzalintinib and Durvalumab for the Treatment of Metastatic or Unresectable Hepatocellular Cancer after Induction Tremelimumab and Durvalumab
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Atezolizumab in Combination with Cyclophosphamide, Sorafenib, and Bevacizumab for the Treatment of Recurrent or Refractory Solid Tumors in Pediatric Patients, ANGIO-A Study
Status: Temporarily Closed to Accrual
Location: 2 locations
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Status: Temporarily Closed to Accrual
Location: Roswell Park Cancer Institute, Buffalo, New York
Distance-Based Exercise to Preserve Function and Prevent Disability (DEFEND)
Status: Active
Location: 17 locations
My Sleep Our Sleep Program to Improve Insomnia in Patients with Stage I-IV Gastrointestinal Cancer and Their Caregivers
Status: Active
Location: 8 locations
A Study of Methylprednisolone to Lower Side Effects in People Having Liver Surgery
Status: Active
Location: 7 locations